Journal for ImmunoTherapy of Cancer (Nov 2023)

674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

  • Faye Johnson,
  • Nashat Gabrail,
  • Ammar Sukari,
  • Barbara Burtness,
  • Christine H Chung,
  • Sara Pai,
  • Lara A Dunn,
  • Cristina Rodriguez,
  • Marya Chaney,
  • Apollina Goel,
  • Ricklie Julian,
  • Francis Worden,
  • Rami Haddad,
  • Douglas Adkins,
  • A Dimitrios Colevas,
  • Laura Agensky,
  • Matteo Levisetti,
  • Steven Margossian,
  • Steve Quayle,
  • Jong Chul Park,
  • Robert M Jotte,
  • Tanguy Y Seiwert,
  • Nabil F Saba,
  • Julie E Bauman,
  • Michael K Gibson

DOI
https://doi.org/10.1136/jitc-2023-SITC2023.0674
Journal volume & issue
Vol. 11, no. Suppl 1

Abstract

Read online

No abstracts available.